Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CTX203
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : aMoon
Deal Size : $93.0 million
Deal Type : Series B Financing
Character Biosciences Raises $93M Series B for Progressive Eye Diseases
Details : The financing aims to fund the clinical development of company's lead product CTX203, which is a potential first-in-class lipid-modulating agent designed for AMD.
Product Name : CTX203
Product Type : Peptide
Upfront Cash : Undisclosed
March 25, 2025
Lead Product(s) : CTX203
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : aMoon
Deal Size : $93.0 million
Deal Type : Series B Financing